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Objective: To determine the impact of COPD on intensive care unit (ICU) mortality in patients
with VAP.
Methods: This prospective observational study was performed in a mixed ICU during a 3-year
period. Eligible patients received mechanical ventilation for >48 h and met criteria for micro-
biologically confirmed VAP. Risk factors for ICU mortality were determined using univariate and
multivariable analyses.
Results: Two hundred and fifteen patients with microbiologically confirmed VAP were
included. Most VAP episodes were late-onset (88%), and Pseudomonas aeruginosa was the most
frequently isolated bacterium (39% of VAP episodes).
ICUmortalitywas significantly lower in non-COPDpatients (nZ 150) compared toCOPDpatients
(nZ 65) (43.3% vs 60%, pZ 0.027, OR [95% CI]Z 1.96 [1.8e3.54]). Duration (days) of mechanical
ventilation and ICU stay median (IQR) in non-COPD patients were 25 (15e42) and 30 (18e48),
whereas in COPD patients were 31 (19e45) and 36 (20e48) (p> 0.05). The differences in duration
(days) of mechanical ventilation and ICU stay were significant between non-COPD patients and
severe COPD (GOLD stage IV) patients (pZ 0.001 and pZ 0.02, respectively). Multivariable anal-
ysis identified COPD [OR (95% CI) 2.58 (1.337e5)], SAPS II [1.024 (1.006e1.024)] and presence of
shock at VAP diagnosis [3.72 (1.88e7.39)] as independent risk factors for ICU mortality.
Conclusion: COPD, SAPS II, and shock at VAP diagnosis are independently associated with ICU
mortality in patients who present VAP.
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n dysfunction; MDR, multidrug resistant; MRSA, methicillin-resistant Staphylococcus aureus; OR, odds
y score; VAP, ventilator-associated pneumonia.
are Unit, Critical Care Department, University Hospital of Thessaly, Biopolis, Larisa 41110, Greece.
1280.
l.com (D. Makris).
1 Elsevier Ltd. All rights reserved.
Mortality in COPD patients with VAP 1023Introduction
heatemoisture exchangers were changed every 48 h orVentilator-associated pneumonia (VAP) is the second most
frequent infection in patients hospitalized in the intensive
care unit (ICU).1 VAP is associated with prolonged duration
of mechanical ventilation and ICU stay and may increase the
need of human resources and the burden of cost in ICU.2 In
addition, VAP is considered as an important determinant of
outcome for critically ill patients.3 Previous studies have
shown that patients who experience VAP have a greater risk
of death compared to patients without the disease although
this was challenged by other investigators.4e6
Prior studies aimed to identify risk factors that may
affect VAP prognosis.7e9 The presence of multidrug resis-
tant (MDR) bacteria, the severity of pneumonia itself and
the application of inadequate initial antibiotic therapy,
have all been identified as determinants of adverse
outcome of patients with VAP. Furthermore, it has been
suggested that the underlying disease leading to ICU
admission might also affect the course of VAP.10 However,
the association between specific underlying diseases and
VAP outcome is not yet clear. COPD is a known risk factor
for VAP occurrence, and is related to risk factors for
adverse VAP outcomes such as MDR bacteria.11 Previous
studies systematically investigating the association
between VAP and COPD are few and COPD populations in
those studies were small whereas COPD severity was not
known.10,12,13
We have previously investigated whether COPD patients
with VAP present increased mortality compared to COPD
patients without VAP. In the present prospective observa-
tional investigation, we followed a large cohort of critically
ill patients who presented VAP and we aimed to evaluate
the impact of COPD on ICU mortality in this population. Our
hypothesis was that COPD would be associated with
increased risk for ICU mortality in VAP patients.
Patients and methods
This study was conducted in a 30-bed ICU at Albert Calm-
ette University Hospital at Lille, France, from November
2006 to June 2009. The local Institutional Review Board
approved the study, and did not require an informed
consent because of the non-interventional design of the
study. This decision was in accordance with the French law.
Eligible patients had received mechanical ventilation for
>48 h and met criteria for microbiologically confirmed VAP.
Patients who were intubated after non-invasive-ventilation
(NIV) failure were included in the study. Patients who
received only NIV were not eligible. Patients were
prospectively screened on a daily basis for inclusion in the
study.
Study population
The oropharyngeal cavity was washed four times a day with
chlorhexidine solution. Continuous subglottic suctioning
was not utilized. The ventilator circuit was not changed
routinely. In all patients a heatemoisture exchanger was
positioned between the Y piece and the patient, themore frequently if visibly soiled. Patients were kept in
semirecumbent position during most of their period of
mechanical ventilation. Tracheal cuff pressure was main-
tained around 25 cm H2O. There was no systematic stress
ulcer prophylaxis and no selective digestive decontamina-
tion. Infection control policy included isolation techniques
in patients with MDR bacteria, written antibiotic treatment
protocol, and continuous surveillance of nosocomial infec-
tions. Sedation and ventilator weaning procedures were
standard throughout the whole study period. NIV was used
in all COPD patients with severe acute exacerbation if there
was no contraindication.Definitions
COPD was defined according to recent ATS/ERS criteria14
and COPD severity was assessed by the Global Initiative
for COPD (GOLD) criteria.15 Definition of VAP included the
presence of new or progressive radiographic infiltrate
associated with two of the three following criteria: 1)
temperature >38.5 C or <36.5 C, 2) leukocyte count
>10 000/mL or <1500/mL, 3) purulent tracheal aspirate. In
addition, a positive tracheal aspirate culture (106 cfu/
mL), or bronchoalveolar lavage culture (104 cfu/mL) was
required to confirm the diagnosis of VAP.15 Only first VAP
episodes occurring >48 h after starting mechanical venti-
lation were taken into account. VAP episodes occurring
<5 d after starting mechanical ventilation were considered
as early-onset. Late-onset VAP was defined as VAP diag-
nosed 5 d after starting mechanical ventilation. Prior
antibiotic use was defined as any antibiotic treatment
during the four weeks preceding ICU admission. Antimi-
crobial therapy was considered inappropriate when none of
the antibiotics used was active in vitro on microorganisms
causing VAP.15
Shock was defined as hypotension which was not
reversed with fluid resuscitation (and required vasopres-
sors) and was associated with organ dysfunction or hypo-
perfusion abnormalities.16 Immunosuppression was defined
as active solid or hematologic malignancy, leucopenia
(<1000/mL), and chronic use of immunosuppressive
therapy.17 Chronic corticosteroid use was considered as
immunosuppressive treatment at 1 mg/kg/day for at least
one month during the 3 months preceding ICU admission.
Long-term low-dose systemic corticosteroid treatment was
defined as corticosteroid treatment at <1 mg/kg/day for at
least one month during the 3 months preceding ICU
admission. During the study period, no HIV infected patient
was admitted to the ICU. MDR bacteria were defined as
methicillin-resistant Staphylococcus aureus (MRSA), cefta-
zidime or imipenem-resistant Pseudomonas aeruginosa,
Acinetobacte baumannii, Stenotrophomonas maltophilia,
and extended-spectrum b-lactamase producing Gram-
negative bacilli. Modified clinical pulmonary infection score
(CPIS)18 was used to assess VAP severity. Radiologic score
was determined by a modification of the technique of
Weinberg et al.19 Anterioreposterior chest roentgenograms
were divided into four zones using a horizontal line origi-
nating from the hilus; each zone was then graded as
1024 D. Makris et al.follows: 0, normal; 1, interstitial pulmonary infiltrates; 2,
fluffy alveolar infiltrates; 3, dense alveolar infiltrates.
Outcomes and study variables
ICU mortality was assessed as a primary outcome in this
study. Duration of mechanical ventilation and ICU stay were
assessed as secondary outcomes.
For all study patients, the following characteristics were
prospectively recorded at admission: age; gender, severity
of illness based on simplified acute physiology score II (SAPS
II), McCabe score,20 logistic organ dysfunction (LOD) score,21
surgery during the last two weeks, presence of co-morbid-
ities, transfer from other wards, infection, shock, long-term
low-dose systemic use of corticosteroids, prior use of anti-
biotics, and findings of the last spirometry in COPD patients.
The following parameters were recorded at the day of VAP
diagnosis: duration of mechanical ventilation prior to VAP,
late-onset VAP, type of causative pathogen, VAP related to
MDR bacteria, polymicrobial VAP, radiographic score, CPIS,
temperature, leukocyte count, albumin level, presence of
shock, use of systemic corticosteroids, and the presence of
acute renal failure as evaluated by the RIFLE scale.22
In addition, information on ICU mortality, total duration
of mechanical ventilation, and length of ICU stay was
collected.
Statistical analysis
Continuous variables were compared using the Student’s t
test for normally distributed variables or the Man-
neWhitney U test for non-normally distributed variables.
The c2or Fisher’s exact test was used to compare categor-
ical variables, as appropriate. To determine the relation-
ship between ICU mortality (dependent variable) and
several independent variables, a multivarable regression
analysis was performed. All variables with a p value <0.1 by
univariate analysis were entered in the forward stepwise
multiple logistic regression model. Results of the logistic
regression analyses are reported as adjusted odds ratios
(ORs) with 95% confidence intervals (CIs).
COPD patients were compared with those without COPD
with regards to characteristics at ICU admission, and at the
day of VAP diagnosis.
Results are expressed as mean  SD or median (25th,
75th interquartile range) for normally and non-normally
distributed continuous variables, respectively. Quantitative
variables are presented as numbers (percentages). All p
values were two-tailed and p values of <0.05 were
considered to indicate statistical significance.
Results
During the study period, 215 patients met criteria for VAP
and were all prospectively followed. Characteristics of
study patients at ICU admission and at the day of VAP
diagnosis are presented in Tables 1 and 2. One-hundred and
fifty seven patients (76%) were admitted due to medical
causes (COPD exacerbation 17.1%, Community-acquired
pneumonia 19.4%, Health-care-associated pneumonia
25.1%, ARDS 2.8%, acute intoxications 10.8%, severecellulites 8%, other causes including cardiac arrest, embo-
lism, pancreatitis 16.6%). The mean mechanical ventilation
duration (days) prior to VAP diagnosis was 18  12.
A total of 235 microrganisms were isolated at significant
threshold. The most frequently isolated microrganisms
were P. aeruginosa (39%), and S. aureus (17% of VAP
episodes). A total of 136 MDR bacteria were isolated in 125
(57%) patients, including 56 (26%) ceftazidime or imipenem-
resistant P. aeruginosa, 30 (13%) A. baumannii, 27 (12%)
ESBL producing Gram-negative bacilli, 16 (7%) MRSA, 7 (3%)
S. maltophilia (Table 3).
Sixty-five out of 215 (30%) patients with VAP had COPD.
Spirometric findings prior to admission were available for 51
out of 65 (78.5%) COPD patients. Forced expiratory volume in
1 s (FEV1) %predicted was 54  16%. According to the GOLD
stages of COPD severity 4(7.8%) of them were stage I,
18(35.2%) stage II, 14(27.4%) stage III and 15(29.5%) stage IV.
Twenty-two out of 65 (33%) COPD patients had long-term
oxygen therapy, 64 (98%) were treated with inhaled bron-
chodilators, 23 (35%) had received corticosteroids during the
last three months, and 4 (6%) had chronic non-invasive-
ventilation at home (Table 3). P. aeruginosa, S. aureus,
Enterobacter species and A. baumannii accounted for 74% of
isolated microrganisms in COPD patients. Table 4 depicts the
distribution of pathogens in COPD according to the GOLD
staging of severity. Age, rate of patients with ultimately or
rapidly fatal disease, rate of patients with infection at ICU
admission, rate of patients with long-term systemic corti-
costeroid use, rate of patients with prior antibiotic treat-
ment, and CPIS were significantly higher in COPD patients
compared to patients without COPD. However, SAPS II and
LOD score were significantly lower in COPD patients
compared to those without COPD. No significant difference
was found in other patient characteristic or microbiological
data between the two groups (Tables 1e3).
Risk factors for ICU mortality
Risk factors for ICU mortality by univariate analysis are
presented in Tables 1 and 2.
Multivariable logistic regression analysis model (Hos-
mereLemshow goodness-of-fit, p Z 0.578) showed that
COPD, SAPS II, and shock at VAP diagnosis were indepen-
dently associated with ICU mortality (Table 5).
Impact of COPD on outcome
ICU mortality was significantly higher in COPD patients
compared to non-COPD patients (60% vs 43% respectively,
p Z 0.027). ICU mortality in the different GOLD stages of
COPD severity were 25%, 82%, 77.5% and 66.5% for stage I,
II, III and IV respectively. No significant difference was
found in mean FEV1 %predicted between survivors and non-
survivors (48  20 vs 45  17%, p Z 0.674). Overall, there
was no significant difference in duration of mechanical
ventilation and length of ICU stay between the COPD and
non-COPD. Durations (days) of mechanical ventilation
median (25th, 75th interquartile range) in survivors were 31
(16e67) and 26 (15e41) for COPD and non-COPD patients
respectively (p Z 0.2). Lengths of ICU stay (days) in survi-
vors were 39 (21e71) and 34 (28e58) for COPD and non-
Table 1 Characteristics of study patients at ICU admission.
Survivors, n Z 111 Non-survivors, n Z 104 p value COPD p value
Yes, n Z 65 No, n Z 150
Age 57  16 65  15 <0.001 68  11 58  17 <0.001
Male gender 82 (73) 78 (75) 0.877 53 (81) 107 (71) 0.128
SAPS II score 48  17 55  17 0.006 47  16 53  18 0.027
McCabe score 2 53 (47) 73 (70) 0.001a 49 (75) 77 (51) 0.001a
LOD score 6.2  4 6.6  4 0.125 5  3 7  4 0.013
Category of admission 0.442 0.013a
Medical 84 (75) 73 (70) 54 (83) 103 (68)
Surgical 27 (24) 31 (29) 11 (16) 47 (31)
Co-morbidities
Immunosuppression 17 (15) 24 (23) 0.167 8 (12) 33 (22) 0.130
Liver cirrhosis 3 (2) 4 (3) 0.714 3 (4) 4 (2) 0.434
Chronic renal failure 4 (3) 4 (3) >0.999 4 (6) 4 (2) 0.247
Diabetes 18 (16) 14 (13) 0.702 7 (10) 25 (16) 0.304
Cancer 13 (10.8) 24 (23) 0.031 10 (15.4) 28 (18.6) 0.841
Cardiac diseaseb 23 (20.7) 29 (27.8) 0.265 21 (32.3) 31 (20.6) 0.086
COPD 26 (23) 39 (37) 0.027a NA NA NA
Transfer from other wards 71 (63) 74 (71) 0.308 45 (69) 100 (66) 0.753
Infection 72 (64) 80 (76) 0.050 53 (81) 99 (66) 0.033a
Shock 30 (27) 44 (42) 0.022a 19 (29) 39 (26) 0.738
Long-term systemic corticosteroid use 6 (5) 10 (9) 0.302 17 (26) 6 (4) <0.001a
Prior antimicrobial treatment 39 (35) 59 (56) 0.002a 37 (56) 61 (40) 0.037a
Data are N (%) or mean  SD. ICU, intensive care unit; SAPS, simplified acute physiology score; LOD, logistic organ dysfunction; COPD,
chronic obstructive pulmonary disease; NA, not applicable.
a Odds ratio (95% CI) 2.6 (1.5e4.5), 2.9 (1.5e5.5), 0.44 (0.21e0.93), 1.9 (1.1e3.5), 2.2 (1.1e4.5), 1.9 (1.1e3.5), 11 (4e29), 2.4
(1.3e4.1), 1.9 (1e3.4); respectively.
b Chronic heart failure or ischemic disease.
Table 2 Characteristics of study patients at the day of VAP diagnosis.
Survivors, n Z 111 Non-survivors, n Z 104 p value COPD p value
Yes, n Z 65 No, n Z 150
Duration of MV prior to VAP 18  11 18  14 0.731 19  14 18  13 0.419
Late-onset VAP 99 (89) 92 (88) >0.999 57 (87) 134 (89) 0.814
VAP related to MDR bacteria 65 (58) 60 (57) 0.889 39 (60) 86 (57) 0.880
Polymicrobial VAP 8 (7) 12 (11) 0.349 4 (6) 16 (10) 0.443
Radiographic score 3.7  1.8 4.6  2.3 0.012 4.6  2.3 3.7  1.8 0.109
CPIS 5.3  1.7 5.5  1.7 0.420 5.8  1.6 5.2  1.7 0.023
PO2/FiO2 250  106 194  100 0.004 207  109 227  105 0.247
Temperature, C 38.1  0.9 37.6  1.4 0.011 38  1 38  1.3 0.796
Leucocytes, cells/mL  103 13.5  7.3 14.8  8.8 0.304 15  8 14  8 0.557
Albumin level, mg/dL 30.7  4.5 28.9  5 0.010 30  4 30  5 0.870
Shock 16 (14) 42 (40) 0.001a 19 (25) 39 (26) 0.738
Use of systemic corticosteroids 30 (27) 45 (43) 0.021a 24 (36) 51 (34) 0.876
Renal failure
Hemodialysis 22 (19) 31 (29) 0.113 16 (24) 37 (24) >0.999
RIFLE 0.165 0.842
Risk 11 (9) 13 (12) 9 (13) 15 (10)
Injury 8 (7) 10 (9) 5 (7) 13 (8)
Failure 16 (14) 22 (21) 14 (21) 24 (16)
Loss 6 (5) 11 (10) 5 (7) 12 (8)
End stage kidney disease 2 (1) 4 (3) 2 (3) 4 (2)
Inappropriate antibiotic treatment 38 (34) 42 (40) 0.471 20 (30) 60 (40) 0.274
MV, mechanical ventilation; VAP, ventilator-associated pneumonia; MDR, multidrug resistant; CPIS, clinical pulmonary infection score.
Data are N (%) or mean  SD.
a Odds ratio (95% CI) Z 3.98 (2.05e7.7), 2.2 (1.1e3.5), respectively.
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Table 3 Microrganisms isolated in 215 patients with VAP.
Survivors, n Z 111 Non-survivors, n Z 104 COPD
Yes, n Z 65 No, n Z 150
Gram-positive
Staphylococcus aureus 18 (16) 19 (18) 10 (15) 27 (18)
Methicillin sensitive 12 (10) 9 (8) 3 (4) 18 (12)
Methicillin resistant 6 (5) 10 (9) 7 (10) 9 (6)
Streptococous pneumoniae 1 (0.9) 0 (0) 0 (0) 1 (0.6)
Gram-negative
Enterobacter species 13 (11) 10 (9) 8 (12) 15 (10)
Haemophilus influenzae 1 (0.9) 0 (0) 1 (1) 0 (0)
Pseudomonas aeruginosa 40 (36) 44 (42) 22 (33) 62 (41)
Serratia marcescensa 7 (6) 1 (0.9) 0 (0) 8 (5)
Proteus mirabilis 2 (1) 1 (0.9) 1 (1) 2 (1)
Acinetobacter baumannii 17 (15) 13 (12) 10 (15) 20 (13)
Escherichia coli 7 (6) 9 (8) 6 (9) 10 (6)
Citrobacter freundi 2 (1) 2 (1) 1 (1) 3 (2)
Stenotrophomonas maltophilia 5 (4) 5 (4) 3 (4) 7 (4)
Klebsiella species 3 (2) 6 (5) 5 (7) 4 (2)
Data are N (%).
a p Z 0.066 for survivors vs non-survivors, p > 0.2 for all other comparisons (survivors vs non-survivors and COPD vs non-COPD
patients).
1026 D. Makris et al.COPD patients respectively (p Z 0.38). However, when
COPD population was stratified according to GOLD stages,
we found that patients with advanced disease (stage IV)
had significantly longer ICU stay and mechanical ventilation
duration compared to patients without COPD (Fig. 1). COPD
stage IV survivors had marginally longer mechanical venti-
lation duration and ICU stay compared to non-COPD survi-
vors [69 (24e103) vs 26 (15e41) respectively, p Z 0.05)]
and [74 (37e113) and 34 (28e58) respectively, p Z 0.07].Discussion
Our findings suggest that the presence of COPD in VAP
patients is an independent risk factor for ICU mortality. InTable 4 Microrganisms isolated in COPD patients according to
COPD stages
IeII, n Z 22
Gram-positive
Staphylococcus aureus 3 (13)
Methicillin sensitive 1 (4)
Methicillin resistant 2 (9)
Gram-negative
Enterobacter species 3 (13)
Pseudomonas aeruginosa 8 (36)
Proteus mirabilis 0 (0)
Acinetobacter baumannii 4 (18)
Escherichia coli 3 (13)
Stenotrophomonas maltophilia 0 (0)
Klebsiella species 1 (4)
Data are N (%) p > 0.05 for all other comparisons.addition, increased SAPS II at ICU admission and the pres-
ence of shock at the day of VAP diagnosis, are also inde-
pendently associated with ICU mortality in VAP patients.
Previous studies reported that COPD was associated with
increased mortality in VAP patients.12,13 However, COPD
was not independently associated with mortality, suggest-
ing that the higher mortality rate observed in these
patients was related to other factors such as various co-
morbidities. In a cohort of 129 VAP patients, including 24
COPD patients, mortality was significantly higher in COPD
patients compared to patients without COPD (33% vs 9%,
p Z 0.002, respectively).13 However, the association
between COPD and VAP mortality did not remain significant
after adjustment for coexisting factors by multivariable
analysis. Similar results were reported by Torres et al.12GOLD staging of COPD severity.
III, n Z 14 IV, n Z 15
3 (21) 4 (26)
1 (7) 1 (6)
2 (14) 3 (20)
3 (21) 2 (13)
6 (43) 5 (33)
1 (7) 0 (0)
1 (7) 1 (6)
1 (7) 1 (6)
0 (0) 1 (6)
0 (0) 1 (6)
Table 5 Risk factors for ICU mortality by multivariable analysis.
Odds ratio 95% CI p value
COPD 2.58 1.33e5.02 0.005
SAPS II 1.02 1.01e1.04 0.010
Shock at the day of VAP
diagnosis
3.72 1.88e7.39 <0.001
COPD, chronic obstructive pulmonary disease; SAPS, simplified acute physiology score.
Mortality in COPD patients with VAP 1027who aimed to identify prognostic factors of nosocomial
pneumonia in mechanically ventilated patients. Neverthe-
less, COPD population was relatively small in those previous
studies and they might have been underpowered to depict
significant differences in ICU mortality in a multivariable
analysis. The present study included a larger COPD pop-
ulation and aimed to investigate as well whether GOLD
staging of COPD severity was associated with the outcomes
of these patients. Our findings provide clear evidence that
COPD is associated with poor prognosis in VAP patients.
Previous studies performed in patients with community-
acquired pneumonia found similar results.23e25
Several factors might explain the higher rates of ICU
mortality in COPD patients with VAP. COPD has an adverse
impact on respiratory muscle function.28 Autopsy findings in
diaphragms of patients with COPD have revealed indices of
increased injury.29 These alterations may be amplified during
critical illness. In our study we have not assessed changes in
respiratory muscle structure or contraction properties.
However, we found no evidence that could support indirectly
the above hypothesis, such as differences in the mechanical
ventilation duration in patients with COPD or not. In addition,
we, and other investigators, have pointed out an association
between COPD and severe acute exacerbations or VAP
secondary to MDR bacteria.11,30,31 Patients with VAP related
to these bacteria are at higher risk for receiving inappropriate
initial antibiotic treatment which has been identified as a risk
factor for mortality in ICU patients.30,32,33 Nevertheless, no
significant difference was found in microbiologic findings and
inappropriate initial antibiotic treatment between COPD andFigure 1 ICU length of stay and mechanical ventilation duration
GOLD staging of COPD severity. Bars represent mean (SE) values.non-COPD patients. In this respect we assume that increased
mortality in critically ill COPD might be related to other
components of the disease. COPD is an inflammatory disease
with complex pathobiology where various underlying mech-
anisms are implicated.26,27 COPD has also a significant
systemic component and patients may be characterized by
nutritional depletion e cachexia28 that may affect adversely
the immune response.34 Certainly, our investigation has not
assessed this hypothesis but this might be the subject of
a future study.
In addition in the present study we investigated whether
COPD is related to longer ICU stay and mechanical venti-
lation. We found no significant association between the
COPD population overall and these indices. When we
analyzed further our data according to GOLD staging of
COPD severity we found that ICU stay and mechanical
ventilation duration were longer in the group with
advanced COPD (GOLD stage IV) compared to non-COPD
patients (Fig. 1). COPD patients with less severe disease
(GOLD stages IeIII) were not different with non-COPD
patients in terms of ICU stay and MV duration. This under-
lines a potential relationship between ICU morbidity and
disease severity. On the other hand, advances or innova-
tions in COPD management in the ICU (i.e. recognition and
management of dynamic hyperinflation) may be more
effective in patients with less severe disease compared to
advanced COPD stages. We acknowledge that definitive
conclusion is hard to be drawn, particularly since there is
luck of data on the relationship between ICU morbidity
indices and COPD staging of severity.in non-COPD patients and patients with COPD, according to the
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gesting that COPD is an independent factor for mortality in
ICU patients who present VAP. Certainly, one might argue
that this finding depends on the quality of adjustment to
potential confounders, which are certainly present in COPD
populations, such as advanced age or medical co-morbid-
ities. Thus, in the present study we assessed several
potential confounders by evaluating baseline characteris-
tics of ICU patients, including co-morbidities (i.e. cardiac
disease, diabetes), severity of critical illness (SAPSII, LOD,
MacCabe score) and parameters related to VAP severity. All
factors which were associated with mortality at the 0.1
level in univariate analysis were forced into the multivari-
able analysis model. Our results (Table 4) suggested that
COPD remained an independent factor of mortality when
confounders were taken into account. Furthermore, it was
revealed that mortality in VAP patients was also indepen-
dently associated to the severity of critical care illness
(SAPSII) and VAP severity (presence of shock at diagnosis).
This might be not surprising since these findings confirm
results reported previously.7,34 However, our study points
out that the significant impact of COPD in the mortality of
patients who present VAP in the ICU.
Inappropriate initial antibiotic treatment was common
(37%) in our population. This could be explained by the high
rate of MDR bacteria (57%) which are frequently resistant to
initial antibiotic regimen. Our study did not find a signifi-
cant relationship between inappropriate initial antibiotic
treatment for VAP and ICU mortality. Two potential expla-
nations could be suggested. First, we did not take into
account timing of antibiotic administration or dose of
antimicrobial therapy. Second, our study was probably
underpowered to detect such an effect.
The present study suggests that outcome in VAP patients is
strongly related to the underlying respiratory disease, such as
COPD. In this respect, our findings might have several clinical
implications in the prevention andmanagement of VAP. First,
existing preventive strategies for VAP should be further
enhanced in COPD population and the effectiveness of more
rigorous protocols should be evaluated, especially in
advanced disease. Furthermore, our findings support the
rigorous use of non-invasive-ventilation in critically ill
COPD.35e37 On the other hand, physicians should be alert not
only for the presence of COPD in the medical history of ICU
patients but also for prompt detection of signs suggestive of
the presence of airflow limitation during mechanical ventila-
tion (i.e. autoPEEP). Moreover, mechanical ventilation strat-
egies that reducehyperinflationandearly adequateantibiotic
treatment should have high priority in these patients. In
addition, parameters reflecting flow limitation might be
helpful in assessing critical illness severity at baseline (i.e. by
including such parameters in ICU severity scores) and finally,
the presence of COPD should be especially considered in
resource planning and family communication issues.
However, at this point we wish to underline that our data
should not be used to withdraw life support in these patients.
Our study has some limitations. First, this study was
performed in a single center. Therefore, our results may
not be generalizable to other ICU patients. Second, several
significant differences were found between COPD and non-
COPD patients. However, multivariable analysis allowed,
at least in part, adjustment for these confounders. Third,one might argue that the incidence of COPD may have been
underestimated in this study. We certainly agree that the
presence of spirometry or a prior diagnosis of COPD was
compulsory for a patient to be treated as a COPD patient in
our study and thus, a selection bias may be possible. Not
all patients who actually have COPD are diagnosed before
critical illness. It is not uncommon for COPD to be diag-
nosed for the first time on the basis of clinical and radio-
logical findings during treatment in the ICU. For example,
patients who have a history of smoking, have distinct signs
of hyperinflation and/or emphysema in the chest X-ray
or those who have expiratory flow limitation during
controlled mechanical ventilation have a very high clinical
probability of actually having COPD. However, such
radiographic or physiologic criteria have not been used in
our study. Thus, the true prevalence of COPD may even be
higher and in this respect the relationship of COPD with
outcome reported in our study is only an estimate; these
issues should be taken into consideration in the interpre-
tation of our results.
In addition, it should be noted that in the present ICU
study spirometry could not be performed at baseline. Thus,
recent spirometry findings were not available for 14 (21%)
COPD patients. In those patients diagnosis was based on
official medical records and medical history obtained by
interviews in ICU. Previous studies in critical care patients
addressing the same issue with the present study have not
provided information with regard the severity of COPD,
therefore any comparison is difficult to be made. This is
a pragmatic limitation of observational ICU studies that
include COPD patients. However, we have repeated
univariate and multivariable analyses after exclusion of
these patients. COPD was still independently associated
with ICU mortality (data not shown).
In conclusion, COPD, SAPS II, and presence of shock at
VAP diagnosis are independently associated with ICU
mortality in patients who present VAP. These data outline
the need to improve the treatment and prevention of VAP
in COPD patients.
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